Aquaculture: Snapper trialled in Tasman Bay open ocean farming system
'Over the last 10 years, we've developed a concept around a mobile aquaculture system that's submerged below the surface and can be moved around.'
The project was granted consent last July after consideration by an independent panel under the now-repealed Covid-19 Recovery (Fast-track Consenting) Act.
The trial system is on a swing mooring, near Rangitoto ki te Tonga, D'Urville Island, at the top of the South Island.
It sits 10-15 metres below the surface, and moves with the tide.
Black said it was a stepping stone toward a fully mobile version.
'That's the vision in the future, so the fish can be transported to the best water temperature that they can grow in and the best water conditions, year-round.'
Black said around 2000 snapper, or tāmure, were transferred to the 500 cubic metre enclosure in April, while the water was warm enough for the first trial, with a focus on how they grow and cope in the pen.
The snapper will be replaced with Chinook salmon for a longer trial over the winter months.
The system is monitored remotely, with scientists able to feed and check on the fish from land through cameras within the pen, alongside visiting the farm at least once a week.
'We need to know that they are content, healthy, that they are being fed and are growing well, and that the water flowing through the pen is at a comfortable flow rate for them.
'The 30-year vision is to have a fully mobile system that is controlled from land, and you don't have people out there, its tootling around in the ocean, the fish are growing their best, living their best lives in a system that's providing everything for them, having the best temperatures, best flow rates, best water quality, that we can control from land.'
The farm was roughly six kilometres from shore, in an area subject to intense weather.
'The hydrodynamics out there are pretty substantial, the wave height can be considerable, and the currents can be considerable as well.
'The storm systems like we're experiencing at the moment, it's giving it a real test, but it's holding up really, really well.'
She said there was a Māori co-innovation group within the research programme, and the scientists worked closely with the eight iwi of Te Tauihu.
The snapper transferred into the pen were about 16 months old and weighed about 200 grams.
They were cultured from wild broodstock caught in Tasman Bay at Plant and Food Research's Port Nelson facility.
Black said that had been important to iwi.
'This is a prototype system, so if something happens where it breaks up and the fish are released, they wanted fish that were going out that were close to wild type as possible.'
Black said a huge amount of work had gone into developing the system with a focus on animal welfare, with the trial farm different from open ocean structures seen in other parts of the world.
'We've taken a soft-engineered approach to this system, we see it as being particularly scalable, and for the infrastructure cost being a lot lower than some of those heavily engineered systems around the world.'
Black said there was a lot of work to be done before the mobile open ocean farm was commercially viable, but she was hopeful of seeing pilot-scale trials happening in the next 10 years.
Oceans and Fisheries Minister Shane Jones launched the New Zealand Aquaculture Development Plan 2025-2030, with the aim of growing the industry's revenue to $3 billion a year by 2035.
Black said the prototype was at the technical feasibility stage and they needed to prove it could be scaled up, was reliable and could withstand wear and tear for a number of years, but ultimately that it could contribute towards generating that revenue.
'We believe that this type of scalable, lower-cost approach to open ocean aquaculture could become a real opportunity, not just for the big players in aquaculture here in New Zealand, but potentially for new players coming in.'
The project has been funded by the Ministry of Business, Innovation and Employment's Endeavour Fund.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
2 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
Press Release – University of Auckland The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period,' she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support. Identifying multiple sclerosis in linked administrative health data in Aotearoa New Zealand New Zealand Medical Journal.
Scoop
2 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
Press Release – University of Auckland The study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006., Lead author Dr Natalia Boven, a postdoctoral fellow from the Universitys COMPASS Research Centre, says. The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period,' she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support.
Scoop
2 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period," she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support. by Natalia Boven, Deborah Mason, Barry Milne, Anna Ranta, Andrew Sporle, Lisa Underwood, Julie Winter-Smith, and Vanessa Selak is published in the 28 March edition of the New Zealand Medical Journal.
